Direct comments to OMB: Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the: Office Management and Budget, Office of Regulatory Affairs, New Executive Office Building, room 10235, Washington, D.C. 20503, Attention: Desk Officer for NIH. To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact: Michele M. Doody, M.S., National Cancer Institute, EPN 408, 6130 Executive Boulevard, Rockville, MD 20892–7364, or call non-toll-free number 301–496–6600.

COMMENTS DUE DATE: Comments regarding this information collection are best assured of having their full effect if received within 30-days of the date of this publication.

Dated: August 5, 1996.

Philip D. Amoruso,

NCI Executive Officer.

[FR Doc. 96–20520 Filed 8–12–96; 8:45 am]

BILLING CODE 4140–01–M

National Institutes of Health

Opportunity for Licensing: Homologous Recombination and Cloning of DNA and Control of Gene Expression

AGENCY: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The National Institutes of Health is seeking licensees and/or CRADA partners for the further development, evaluation, and commercialization of homologous recombination and cloning of DNA and control of gene expression. The inventions claimed in the patents and patent applications referenced below under Supplementary Information are available for either exclusive or non-exclusive licensing (in accordance with 35 U.S.C. 207 and 37 CFR Part 404) and/or further development under a CRADA for clinical and research applications.

ADDRESSES: Questions about this licensing opportunity should be addressed to: Larry Tiffany, J.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/496–7735, ext. 206; fax: 301/402–0220.

Questions about a CRADA opportunity should be addressed to: Dr. Cyrus R. Creveling, Director, Office of Technology Transfer, National Institute of Diabetes and Digestive and Kidney Diseases, Building 31, Room 9A35, 9000 Rockville Pike, Bethesda, MD 20892; telephone: 301/496–5360; fax: 301/496–2830.

SUPPLEMENTARY INFORMATION: The isolation and cloning of genomic DNA fragments is a fundamental technique in molecular biology. Several methods are available to amplify and isolate selected DNA fragments, the common being polymerase chain reaction (PCR). Major limitations in PCR are its error rate and the small fragment size which may be reliably amplified. The *E. coli* enzyme RecA has the ability to specifically target single-stranded DNA to complementary target duplex DNA to create a three-stranded complex.

The present technology involves the use of *E. coli* RecA protein and peptides derived from it for: (1) Targeting restriction endonuclease cleavage to unique predetermined sites, (2) sequence specific mapping and manipulation of complex genomes, (3) diagnosing a genetic mutation, and (4) developing therapeutics: site specific gene inactivation, correction of gene mutations, control of gene expression.

These inventions are embodied in the following patents and patent applications:

U.S. Patent 5,460,941—''Method of Targeting DNA''

U.S. Patent 5,510,473—''Cloning of the RecA Gene from Thermus Aquaticus YT–1''—and its DIV, U.S. Patent Application Serial No. 08/446,413

U.S. Patent Application Serial No. 08/483,115—''RecA Peptide''

U.S. Patent Application Serial No. 60/001,384—''RecA Assisted Cloning of DNA''

Information about the patent applications and pertinent information not yet publicly described can be obtained under a Confidential Disclosure Agreement. Respondees interested in licensing the invention(s) will be required to submit an Application for License to Public Health Service Inventions.

To expedite the research, development, and commercialization of these compounds, the National Institutes of Health will also consider a CRADA with a pharmaceutical or biotechnology company in accordance with the regulations governing the transfer of Government-developed agents. Any proposal to use or develop these compounds will be considered. Respondees interested in submitting a CRADA proposal should be aware that it may be necessary to secure a license to the above patent rights in order to commercialize products arising from a CRADA.

Dated: August 5, 1996.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 96–20521 Filed 8–12–96; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR–4086–N–22]

Office of the Assistant Secretary for Public and Indian Housing; Notice of Proposed Information Collection for Public Comment

AGENCY: Office of the Assistant Secretary for Public and Indian Housing, HUD.

ACTION: Notice.

SUMMARY: The proposed information collection requirement described below will be submitted to the Office of Management and Budget (OMB) for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal.

DATES: Comments due: October 15, 1996.

ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB Control Number and should be sent to: Mildred M. Hamman, Reports Liaison Officer, Public and Indian Housing, Department of Housing and Urban Development, 451—7th Street, SW, Room 4238, Washington, D.C. 20410–5000.

FOR FURTHER INFORMATION CONTACT: Mildred M. Hamman, (202)–708–0846, for copies of the proposed forms and other available documents. (This is not a toll-free number).

SUPPLEMENTARY INFORMATION: The Department will submit the proposed information collection to OMB for review, as required by the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35, as amended).

This Notice is soliciting comments from members of the public and affected agencies concerning the proposed collection of information to: (1) evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the